血浆cofilin蛋白检测在肺癌诊断中的价值

Detection of plasma cofilin protein for diagnosis of lung cancer

目的检测肺癌患者血浆cofilin蛋白的含量,探讨其临床应用价值。方法分别抽取30例未手术肺癌患者及30例健康人的血液作为研究对象,采用酶联免疫吸附法(Elisa)检测上述血浆中cofilin蛋白含量,分析肺癌患者血浆cofilin蛋白含量与健康人血浆cofilin蛋白含量的差异。结果肺癌患者血浆中cofilin蛋白含量是0.485±0.465 ng/ml,健康人血浆cofilin蛋白含量0.203±0.102 ng/ml,两者比较有统计学差别(P<0.05)。Ⅲ、Ⅳ期肺癌患者血浆中cofilin蛋白含量0.744±0.584 ng/ml,Ⅱ期肺癌患者血浆中cofilin蛋白含量0.257±0.126 ng/ml,两者比较有统计学差别(P<0.05)。结论肺癌患者血浆cofilin蛋白的含量高于健康人血浆cofilin蛋白含量(P<0.05),提示血浆cofilin蛋白含量和肺癌相关。Ⅲ、Ⅳ期肺癌患者血浆中cofilin蛋白含量高于Ⅱ期肺癌患者,提示血浆cofilin蛋白含量和肺癌分期相关。

Objective To detect serum content of cofilin protein in patients with lung cancer and investigate its clinical value. Methods The serum content of cofilin protein was detected in 30 cases of lung cancer and 30 healthy control subjects using enzyme-linked immunosorbent assay. Results The mean serum content of cofilin protein was 0.485±0.465 ng/ml in patients with lung cancer and 0.203±0.102 ng/ml in the control subjects, showing a significant difference between them （P〈0.05）. The content of cofilin protein in patients with stage III and IV lung cancer 0.744±0.584 ng/ml, significantly higher than that in stage Ⅱ patients （0.257±0.126 ng/ml）. Conclusion Serum cofilin protein is elevated in patients with lung cancer, especially in cases in advanced stages, suggesting its relation with lung cancer staging.